£12 million investment for Oxford University Innovation spin-out Nightstar
Wellcome Trust's VC arm backs an Isis spinout developing a gene therapy for inherited blindness.
We publish news of technology innovations, investment opportunities, together with updates from spin-out & start-up companies and licensees
Wellcome Trust's VC arm backs an Isis spinout developing a gene therapy for inherited blindness.
'Imagine a piece of software that would allow the soldiers, aid workers and government officials thrown together after a disaster to quickly and securely communicate with each other whatever device they hold in their hands....
Oxford Immunotec announces preliminary fourth quarter revenues
Oxford University Innovation announced that OxSonics has raised £2.7 million to develop therapeutic technology which uses ultrasound devices in combination with ultrasound-sensitive nanoparticles.
Immunocore has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca.
Colwiz has announced the launch of the first HTML5 interactive PDF reader.
Reviving a gene which is “turned down” after birth is potentially the key to treating Duchenne Muscular Dystrophy, an untreatable muscle-wasting condition which affects one in every 3,500 boys.
Oxford Immunotec – a 2002 Isis spin-out – has raised US$64 million in an IPO on America’s Nasdaq stock exchange. The Abingdon-based company sells diagnostic tests for latent tuberculosis infection, T-SPOT®.TB.
Immunocore Limited, the Oxford based biotechnology company developing novel biological drugs to treat cancer and viral disease has announced the achievement of its first milestone in its research and licensing agreement with GlaxoSmithKline.
Oxford University Innovation spin-outs, Oxford Gene Technology and OrganOx have won an award each at the OBN Annual Awards Dinner held on 1st October. The OBN is a membership organisation supporting and bringing together the UK’s emerging life science R&D companies, their corporate partners and investors.